Dynavax Technologies Corporation

Schering Corporation

New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery

Franck J Barrat

Cristiana Guiducci

Robert L Coffman

Tracy Matray

Rene De Waal Malefyt

Karen L Fearon

Anne O'Garra

Pieter Andre Boonstra

Huub Savelkoul

The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using CXC chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.

Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines

Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.

Human toll-like receptor inhibitors and methods of use thereof

The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.

Methods and compositions for inhibition of immune responses and autoimmunity

The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.

Methods of treatment using TLR7 and/or TLR9 inhibitors

Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic s and methods of use thereof.

Transgenic mice expressing human toll-like receptor 8

The invention provides immunoregulatory polynucleotides and methods for immunoregulation of individuals using the immunoregulatory polynucleotides.

Methods and compositions for inhibition of innate immune responses and autoimmunity

Methods for increasing yields of regulatory T cells, useful, e.g., in transplantation contexts. Use of antigen presenting cells and anti-CD28 are also described.

Growing community of inventors

San Mateo, CA, United States of America

Franck J Barrat